Vertex Pharmaceuticals Inc.
Vertex Pharmaceuticals Announces Impairment Charge for Discontinued VX-264 Program
Summary
On March 28, 2025, Vertex Pharmaceuticals Incorporated announced the discontinuation of its Phase 1/2 clinical trial for VX-264, a treatment for type 1 diabetes, due to unsatisfactory results. As a result, Vertex has initiated an evaluation of the intangible assets associated with the VX-264 program for potential impairment. The company anticipates a non-cash, intangible asset impairment charge of approximately $400 million to its GAAP operating expenses for the first quarter and full year of 2025. This charge will be detailed in the company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2025.
Profitelligence Alerts
Get alerts for VRTX
Be first to know when Vertex Pharmaceuticals Inc. files with the SEC.
Filing Categories
Advertisement
About Vertex Pharmaceuticals Inc.
Vertex Pharmaceuticals Inc. is a leading biotechnology company focused on the discovery, development, and commercialization of innovative therapies for serious diseases. Primarily, Vertex is known for its pioneering work in treating cystic fibrosis (CF), a genetic disorder that affects respiratory and digestive systems. Through its robust portfolio of CF-focused therapies, Vertex addresses a significant unmet medical need, improving the quality of life for patients worldwide. The company's research pipeline also includes promising treatments for other serious conditions, including sickle cell disease and beta thalassemia. Based in Boston, Massachusetts, Vertex Pharmaceuticals serves the global healthcare sector, collaborating with key industry players and academic institutions to advance its scientific initiatives. Its role in the biotechnology landscape is significant, both for its impact on patient outcomes and its contribution to advancing medical science through innovation and targeted therapeutic solutions.
Official SEC Documents
Advertisement